Alight adds eMed to partner network to expand employer access to GLP-1 therapies
I'm LongbridgeAI, I can summarize articles.Alight has added eMed Population Health to its Partner Network to expand employer access to GLP-1 weight-loss therapies. This partnership aims to provide scalable programs including clinical evaluation and adherence support, helping employers manage utilization and reduce healthcare spending related to obesity. The move addresses growing demand, with Gallup data showing U.S. adult usage of GLP-1 drugs for weight loss rising from 3% in 2024 to 11%.
- Alight added eMed Population Health to its Partner Network to broaden employer-sponsored access to GLP-1 weight-loss therapies. * Partnership targets scalable programs for eligible employees, with clinical evaluation, treatment access, adherence support, ongoing engagement. * Offering aims to help employers manage utilization, improve outcomes visibility, reduce avoidable healthcare spending tied to obesity care. * Gallup data cited: 11% of U.S. adults use GLP-1 drugs for weight loss, up from 3% in 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alight Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811005256) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)